This article summarized the latest R&D progress of Neostigmine Methylsulfate, the Mechanism of Action for Neostigmine Methylsulfate, and the drug target R&D trends for Neostigmine Methylsulfate.
Pierre Fabre Laboratories takes over Vertical Bio along with its ground-breaking, targeted therapy candidate for patients battling MET-altered Non-Small Cell Lung Cancer.
This article summarized the latest R&D progress of Milrinone Lactate, the Mechanism of Action for Milrinone Lactate, and the drug target R&D trends for Milrinone Lactate.
This article summarized the latest R&D progress of Midazolam Hydrochloride, the Mechanism of Action for Midazolam Hydrochloride, and the drug target R&D trends for Midazolam Hydrochloride.
Insilico Medicine and Exelixis, Inc. announced a licensing agreement allowing Exelixis to globally produce and market ISM3091, a promising USP1 inhibitor related to BRCA-altered cancers.
This article summarized the latest R&D progress of Metreleptin, the Mechanism of Action for Metreleptin, and the drug target R&D trends for Metreleptin.
Leukotriene antagonists work by blocking the action of leukotrienes, they are mainly used for preventing asthma, controlling allergic rhinitis or allergic reactions.
BioLineRx Discloses FDA Authorization for APHEXDA™ (motixafortide), to Activate Hematopoietic Stem Cells for Gathering and Subsequent Autologous Transplantation in Multiple Myeloma Patients.
This article summarized the latest R&D progress of Ixabepilone, the Mechanism of Action for Ixabepilone, and the drug target R&D trends for Ixabepilone.
The Lymphocyte-activation gene-3 (LAG-3) is located on human chromosome 12 (20p13.3), includes 8 exons, and its corresponding cDNA encodes a membrane protein containing 498 amino acids.